Alzheimer's disease: Why do brain cells die? Study offers new clues

Evan Walker
Evan Walker TheMediTary.Com |
an illustration of brain cells and neuronsShare on Pinterest
A study offers new clues on a potential cause of neuron death in Alzheimer’s disease. Jose A. Bernat Bacete/Getty Images
  • About 32 million people globally have Alzheimer’s disease.
  • While scientists are still unclear as to the true cause of Alzheimer’s disease, they do know a loss of neurons in the brain plays an important role.
  • A new study from researchers at Northwestern University has found a possible new cause of neuron death in Alzheimer’s through toxic RNA strands.

Alzheimer’s disease is the most common form of dementia and is estimated to affect about 32 million people worldwide.

While scientists are still unclear as to the true cause of Alzheimer’s disease, they do know a loss of neurons in the brain plays an important role.

Now, in a new study published in the journal Nature Communications, researchers from Northwestern University have found a possible new cause of neuron death in Alzheimer’s through toxic RNA strands.

For many years, the common consensus among researchers is that clumps of beta-amyloid proteins called plaques and tau proteins called tangles within the brain are the main cause of Alzheimer’s disease.

“These proteins are certainly involved and important,” Dr. Peter said. “However, it could never be shown how exactly they result in the death of neurons. Our work now provides a new model for how that occurs. The toxic sRNAs are downstream of these two proteins. We believe that they are the executioners.”

When asked if these new RNA-based findings might result in new treatments for Alzheimer’s disease, Dr. Peter said this new avenue still needs to be explored:

“In our paper, we show that stabilizing or increasing the amount of protective sRNAs or inhibiting the toxic sRNAs can rescue cells from cell death. This provides new avenues for drug development to treat AD and potentially other neurodegenerative diseases.

“(Research next steps include) testing our concept in more animal models and in Alzheimer’s disease patients derived neurons and postmortem brain tissues,” Dr. Peter continued. “Then screening and testing for drugs that either increase the level of the protective sRNAs or reduce the activity of the toxic ones. There are concepts and ideas that need to be and can be tested now.”

After reviewing this study, Dr. Karen D. Sullivan, a board certified neuropsychologist, owner of I CARE FOR YOUR BRAIN, and Reid Healthcare Transformation Fellow at FirstHealth of the Carolinas in Pinehurst, NC, told MNT that the insights gained from this study give us a better understanding of both what goes very wrong in the aging brain via Alzheimer’s disease and what goes very right in the aging brain with SuperAgers.

“It also gives hope for a novel intervention pathway to stop or slow down this devastating neurodegenerative disease,” Dr. Sullivan continued. “Over 90% of current Alzheimer’s disease research efforts focus on the compounds amyloid and tau. This study suggests that another disease process, RNA, may be a target for future treatments.”

MNT also spoke about the study with Dr. Clifford Segil, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA.

Dr. Segil said he is cautiously optimistic that RNA-based therapies that are being introduced for many diseases will have good clinical neurological applications.

“This study clearly showed that there is neurotoxicity related (to) the genes that they looked at,” he continued. “The study is also trying to state that there (are) neuroprotective benefits from these types of medications and other disease states.”

“I’m hopeful that something like an mRNA-based therapy can be neuroprotective in humans, given the right research in other animals working up to humans one day,” Dr. Segil added. “I think it’s optimistically cautious.”

TAGGED: , , , ,
Share this Article